Rare diseases specialist Swedish Orphan Biovitrum (Sobi) agreed to buy the drug emapalumab and is reorganizing to increase focus on late-stage development in hematology and immunology.
Catalyst Pharmaceuticals Inc., under fire for a high price tag on a rare disease drug, sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival medicine.
Digital Science launched a report on the state of open access monographs. The report addresses the question of how the company integrates and values monographs in the increasingly open digital scholarly network.
Denmark-based Genmab A/S and Janssen Biotech will collaborate on a successor to the multiple myeloma drug Darzalex with the development of a next-generation CD38 antibody product for the treatment of multiple myeloma and diffuse large B-cell lymphoma.
Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.
Merck & Co. Inc. agreed to buy privately held Tilos Therapeutics for up to $773 million, bolstering the drugmaker‘s pipeline to treat cancer and autoimmune diseases.
Merck agreed to acquire Tilos, a privately held biopharma company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.
Swiss drugmaker Roche’s $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics was pushed back again, possibly beyond first-half 2019, as regulators continue to scrutinize the deal’s effect on competition.
The 2019 BIO International Convention held in Philadelphia included more than 16,000 attendees from 67 countries and thousands of presentations.
In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.